Tech Company Financing Transactions
OncoMed Pharmaceuticals Funding Round
OncoMed Pharmaceuticals closed a $3 million funding round on 12/31/2006. Investors included Morgenthaler Ventures and U.S. Venture Partners.
Transaction Overview
Company Name
Announced On
12/31/2006
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Morgenthaler Ventures (Paul Hastings)
U.S. Venture Partners (Jonathan Root)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
800 Chesapeake Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
OncoMed Pharmaceuticals (NASDAQ: OMED) is discovering and developing monoclonal antibodies and small molecules capable of destroying cancer stem cells, a recently discovered type of cell believed to seed the growth of cancers and underlie cancer's ability to spread and take root in tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Lewicki
Chief Scientific Officer
Austin Gurney
Vice President
Ann Kapoun
VP - Finance
Yvonne Li
VP - General Counsel
Alicia Hager
VP - R & D
Robert Stagg
VP - Regulatory Affairs
Jill Henrich
Browse more venture capital transactions:
Prev: 12/31/2006: RivalWatch venture capital transaction
Next: 12/31/2006: Medlogics Device venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs